NULISA (nucleic acid linked immuno-sandwich assay), from Alamar Biosciences, reads hundreds of proteins at once with sensitivity down to fg/mL. That puts cytokines and CNS markers that sit below the floor of an ELISA within reach. We run the six NULISAseq panels below, and we build custom NULISAqPCR assays when no panel covers your target.
NULISA pairs a two-antibody sandwich with a DNA barcode readout. Each antibody carries an oligonucleotide; when both bind the same protein the two oligos are ligated, then amplified and counted by sequencing. Two rounds of capture and release strip away the sample background before amplification, which is where most of the sensitivity comes from.
In practice, that means proteins present at fg/mL, including many cytokines in healthy plasma, come back with values instead of "below LOD". The dynamic range is wide enough that high- and low-abundance proteins are read in the same well without dilution.
Runs are automated on Alamar's ARGO HT instrument. Median CVs are under 10%, and the same panel can be run across batches with bridging.
Alamar's newest and broadest immune panel, released in July 2026. It builds on the Inflammation 250 content and adds checkpoint proteins, metabolic regulators, cell-death mediators and co-stimulatory molecules, many of which circulate at fg/mL to sub-pg/mL and are not seen on other platforms. We'd point immuno-oncology and inflammaging studies here first.
The workhorse immunology panel: 250 cytokines, chemokines, growth factors and soluble receptors in one run. Most inflammation, autoimmune, infectious disease and oncology studies that come to us for NULISA start here. If you need concentrations in pg/mL for a subset, look at the AQ version below.
The same breadth as Inflammation 250, with calibrated concentrations in pg/mL for more than 150 of the targets. Choose it when the numbers have to line up across studies, sites or years: PK/PD, toxicology, longitudinal cohorts and anything headed for a regulatory filing.
A CNS panel with the established Alzheimer's markers on it (Abeta42, Abeta40, pTau181, pTau217, NfL, GFAP), along with synaptic proteins, neuroinflammatory mediators, glial markers and alpha-synuclein. The sensitivity is what makes it useful in plasma as well as CSF: markers that are only reliably measurable in CSF on other platforms come through in blood here.
A smaller CNS panel for when the hypothesis is already defined. The CNS Disease 120 covers the core neurodegeneration, neuroinflammation and synaptic markers at the same fg/mL sensitivity, at a lower cost per sample than the Neuro 220. It's a reasonable choice for validation after a broader run, or for smaller cohorts.
The NULISA panel for animal studies. It reads 120 mouse proteins across immune, inflammatory, metabolic and neurological biology, and the antibodies cross-react with rat, so both species can go on the same panel without separate assay development. Useful for carrying a biomarker from a mouse model into a human cohort on the same technology.
All six run on the ARGO HT with fg/mL sensitivity, ~12 logs of dynamic range and median CVs under 10%.
| Panel | Proteins | Species | Quantification | Typical use |
|---|---|---|---|---|
| Immune 340 | ~340 | Human | Relative | Immuno-oncology, checkpoints, inflammaging |
| Inflammation 250 | 250 | Human | Relative | Broad immune profiling, autoimmune, infection |
| Inflammation AQ | 250+ (150+ absolute) | Human | Relative + absolute | PK/PD, longitudinal, multi-site trials |
| Neuro 220 | 220 | Human | Relative | CNS discovery: AD, PD, ALS, MS, TBI |
| CNS Disease 120 | 120 | Human | Relative | Focused CNS hypotheses and validation |
| Mouse 120 | 120 | Mouse, rat | Relative | Preclinical and translational studies |
Tell us the species, the sample type and the biology you care about. We'll recommend a panel, flag anything that might not work, and send a quote within one business day.
Request a quote